• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

自体干细胞移植后复发的套细胞淋巴瘤：单中心经验

Mantle cell lymphoma relapsed after autologous stem cell transplantation: a single-center experience.

作者信息

Wu Aaron, Graf Solomon A, Burwick Nicholas, Grim Jonathan E, Dong Zhao Ming, Richard Robert E, Chauncey Thomas R

机构信息

Department of Hospital and Specialty Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.

Division of Oncology, University of Washington Medicine, Seattle, WA, USA.

出版信息

Blood Res. 2020 Mar;55(1):57-61. doi: 10.5045/br.2020.55.1.57. Epub 2020 Mar 30.

DOI:10.5045/br.2020.55.1.57
PMID:32269976
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7106113/
Abstract

BACKGROUND

Autologous stem cell transplantation (autoSCT) can extend remission of mantle cell lymphoma (MCL), but the management of subsequent relapse is challenging.

METHODS

We examined consecutive patients with MCL who underwent autoSCT at Veterans Affairs Puget Sound Health Care System between 2009 and 2017 (N=37).

RESULTS

Ten patients experienced disease progression after autoSCT and were included in this analysis. Median progression free survival after autoSCT was 1.8 years (range, 0.3-7.1) and median overall survival after progression was only 0.7 years (range, 0.1 to not reached). The 3 patients who survived more than 1 year after progression were treated with ibrutinib.

CONCLUSION

Our findings suggest that ibrutinib can achieve relatively prolonged control of MCL progressing after autoSCT.

摘要

背景

自体干细胞移植（autoSCT）可延长套细胞淋巴瘤（MCL）的缓解期，但后续复发的管理具有挑战性。

方法

我们研究了2009年至2017年间在普吉特海湾退伍军人事务医疗保健系统接受autoSCT的连续性MCL患者（N = 37）。

结果

10例患者在autoSCT后出现疾病进展，并纳入本分析。autoSCT后的无进展生存期（PFS）中位数为1.8年（范围0.3 - 7.1年），进展后的总生存期（OS）中位数仅为0.7年（范围0.1年至未达到）。3例进展后存活超过1年的患者接受了伊布替尼治疗。

结论

我们的研究结果表明，伊布替尼可实现对autoSCT后进展的MCL的相对长期控制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c7d/7106113/e5aea1ca1a45/br-55-57-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c7d/7106113/2d686f356464/br-55-57-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c7d/7106113/f33e8e06623b/br-55-57-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c7d/7106113/e5aea1ca1a45/br-55-57-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c7d/7106113/2d686f356464/br-55-57-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c7d/7106113/f33e8e06623b/br-55-57-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c7d/7106113/e5aea1ca1a45/br-55-57-g003.jpg

相似文献

1
Mantle cell lymphoma relapsed after autologous stem cell transplantation: a single-center experience.自体干细胞移植后复发的套细胞淋巴瘤：单中心经验
Blood Res. 2020 Mar;55(1):57-61. doi: 10.5045/br.2020.55.1.57. Epub 2020 Mar 30.
2
Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).自体造血干细胞移植后复发的套细胞淋巴瘤患者的预后和影响因素：欧洲血液和骨髓移植组（EBMT）的回顾性研究。
Ann Oncol. 2014 May;25(5):1053-8. doi: 10.1093/annonc/mdu097. Epub 2014 Feb 27.
3
Long-Term Survival of Patients with Mantle Cell Lymphoma after Total Body Irradiation, High-Dose Chemotherapy and Stem Cell Transplantation: A Monocenter Study.全身照射、大剂量化疗及干细胞移植后套细胞淋巴瘤患者的长期生存：一项单中心研究
Cancers (Basel). 2023 Feb 3;15(3):983. doi: 10.3390/cancers15030983.
4
Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience.自体造血干细胞移植治疗原发性难治或复发性霍奇金淋巴瘤的疗效：单中心长期随访经验
Ann Hematol. 2020 Feb;99(2):265-276. doi: 10.1007/s00277-019-03900-x. Epub 2020 Jan 2.
5
[Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].风险适应性强化诱导治疗、自体干细胞移植和利妥昔单抗维持治疗可使套细胞淋巴瘤患者达到较高的7年生存率。
Ter Arkh. 2019 Jul 15;91(7):41-51. doi: 10.26442/00403660.2019.07.000322.
6
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.EBMT/EMCL 共识项目关于自体和异基因干细胞移植在套细胞淋巴瘤中的作用。
Leukemia. 2015 Feb;29(2):464-73. doi: 10.1038/leu.2014.223. Epub 2014 Jul 18.
7
Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).异基因造血干细胞移植治疗套细胞淋巴瘤：德国东部血液学和肿瘤学研究组前瞻性试验（OSHO#60 和 #74）更新。
Ann Hematol. 2021 Jun;100(6):1569-1577. doi: 10.1007/s00277-021-04506-y. Epub 2021 Apr 8.
8
Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse.依鲁替尼联合R-ICE方案可诱导中枢神经系统复发的母细胞样变异型套细胞淋巴瘤缓解。
Case Rep Hematol. 2022 May 6;2022:1930546. doi: 10.1155/2022/1930546. eCollection 2022.
9
Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL.成功进行异基因干细胞移植并采用预防性逐步使用粒细胞集落刺激因子（G-CSF）预处理的供者淋巴细胞输注（DLIs）治疗套细胞淋巴瘤自体移植后复发：1例病例报告及关于套细胞淋巴瘤中移植物抗淋巴瘤（GVL）效应证据的文献综述
Am J Hematol. 2000 Sep;65(1):75-80. doi: 10.1002/1096-8652(200009)65:1<75::aid-ajh14>3.0.co;2-l.
10
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.利妥昔单抗治疗后复发/难治滤泡性淋巴瘤的干细胞移植：来自 NCCN 淋巴瘤结局项目的综合分析。
Cancer. 2013 Oct 15;119(20):3662-71. doi: 10.1002/cncr.28243. Epub 2013 Aug 6.

本文引用的文献

1
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.利妥昔单抗时代年轻套细胞淋巴瘤患者的生存结局。
J Clin Oncol. 2019 Feb 20;37(6):471-480. doi: 10.1200/JCO.18.00690. Epub 2019 Jan 7.
2
Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.异基因造血细胞移植对伴有 TP53 改变的套细胞淋巴瘤患者结局的影响。
Br J Haematol. 2019 Mar;184(6):1006-1010. doi: 10.1111/bjh.15721. Epub 2018 Dec 11.
3
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.
基于大剂量阿糖胞苷方案的套细胞淋巴瘤进展时间可确定患者的死亡风险。
Br J Haematol. 2019 Jun;185(5):940-944. doi: 10.1111/bjh.15643. Epub 2018 Nov 8.
4
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).来那度胺治疗预处理的套细胞淋巴瘤患者：意大利真实世界多中心回顾性研究（Lenamant 研究）。
Oncologist. 2018 Sep;23(9):1033-1038. doi: 10.1634/theoncologist.2017-0597. Epub 2018 Apr 19.
5
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.伊布替尼联合维奈托克治疗套细胞淋巴瘤。
N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.
6
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.套细胞淋巴瘤自体干细胞移植后利妥昔单抗的应用。
N Engl J Med. 2017 Sep 28;377(13):1250-1260. doi: 10.1056/NEJMoa1701769.
7
Chimeric antigen receptor T-cell therapies for lymphoma.嵌合抗原受体 T 细胞疗法治疗淋巴瘤。
Nat Rev Clin Oncol. 2018 Jan;15(1):31-46. doi: 10.1038/nrclinonc.2017.128. Epub 2017 Aug 31.
8
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.370例接受依鲁替尼治疗的套细胞淋巴瘤患者的结局：三项开放标签研究的汇总分析
Br J Haematol. 2017 Nov;179(3):430-438. doi: 10.1111/bjh.14870. Epub 2017 Aug 18.
9
mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.突变可识别出年轻的套细胞淋巴瘤患者，他们不能从强化化疗免疫治疗中获益。
Blood. 2017 Oct 26;130(17):1903-1910. doi: 10.1182/blood-2017-04-779736. Epub 2017 Aug 17.
10
New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.适用于福尔马林固定石蜡包埋活检组织的套细胞淋巴瘤增殖特征新分子检测法。
J Clin Oncol. 2017 May 20;35(15):1668-1677. doi: 10.1200/JCO.2016.70.7901. Epub 2017 Mar 14.